Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Fairfax, Virginia

Phase 3 cancer trials in Fairfax, VA

54 Phase 3 cancer studies are recruiting participants at sites in Fairfax as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Fairfax at a glance

Breast cancer studies recruiting in Fairfax

Basic details from each study's public record (the 30 most recently updated of 54). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT07683754 · updated
  2. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    Virginia Cancer Specialists, PC
    Registry record
    NCT06982521 · updated
  3. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study site
    Inova Fairfax Hospital
    Registry record
    NCT05633654 · updated
  4. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Inova Fair Oaks Hospital · Inova Schar Cancer Institute
    Registry record
    NCT06748222 · updated
  5. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT07174336 · updated
  6. BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT07492641 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.

Lung cancer studies recruiting in Fairfax

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  2. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Virginia Cancer Specialists, PC
    Registry record
    NCT07195695 · updated
  3. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Virginia Cancer Specialists ( Site 0167)
    Registry record
    NCT06623422 · updated
  4. A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eikon Therapeutics
    Study site
    Virginia Cancer Specialists, PC
    Registry record
    NCT07365319 · updated
  5. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Virginia Cancer Specialists ( Site 0114)
    Registry record
    NCT07554339 · updated
  6. BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT07625644 · updated
  7. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07291037 · updated
  8. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    USO - Virginia Cancer Specialists
    Registry record
    NCT06119581 · updated
  9. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study sites
    Inova Schar Cancer · Virginia Cancer Specialists
    Registry record
    NCT06712316 · updated
  10. Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

    • Phase 3
    • Ages 18 to 90
    • All sexes
    Sponsor
    ImmunityBio, Inc.
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT06745908 · updated
  11. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ArriVent BioPharma, Inc.
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT07185997 · updated
  12. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Mirati Therapeutics Inc.
    Study site
    USOR - Virginia Cancer Specialists - Fairfax Office
    Registry record
    NCT04613596 · updated
  13. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06692738 · updated
  14. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06627647 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Fairfax

  1. A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    BioNTech SE
    Study site
    Virginia Cancer Specialists PC
    Registry record
    NCT07365995 · updated
  2. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT07164443 · updated
  3. A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT07225946 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.

Melanoma studies recruiting in Fairfax

  1. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Inova Schar Cancer Institute
    Registry record
    NCT06246916 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Fairfax, VA on ClinicalTrials.gov.

Lymphoma studies recruiting in Fairfax

  1. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Study site
    Inova Schar Cancer Institute
    Registry record
    NCT05303519 · updated
  2. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Inova Schar Cancer Institute ( Site 0015)
    Registry record
    NCT06136559 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Fairfax, VA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Fairfax

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study sites
    Investigative Site US057 · Investigative Site US065
    Registry record
    NCT07522073 · updated
  2. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immuneering Corporation
    Study site
    Virginia Cancer Specialists
    Registry record
    NCT07562152 · updated
  3. A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Inova Schar Cancer Institute Clinical Trials
    Registry record
    NCT07409272 · updated
  4. Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Virginia Cancer Specialists - Fairfax Office
    Registry record
    NCT06943755 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.

Ask about studies near Fairfax

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Virginia

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call